Phoenix Financial Ltd. Purchases 6,332 Shares of Johnson & Johnson $JNJ

Phoenix Financial Ltd. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 13.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,162 shares of the company’s stock after purchasing an additional 6,332 shares during the period. Phoenix Financial Ltd.’s holdings in Johnson & Johnson were worth $13,804,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Jupiter Topco LLC acquired a new position in Johnson & Johnson in the 2nd quarter worth $1,967,399,000. Corient Private Wealth LP grew its stake in shares of Johnson & Johnson by 127.3% during the second quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company’s stock valued at $1,539,292,000 after acquiring an additional 3,393,981 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after acquiring an additional 2,513,321 shares in the last quarter. Amundi grew its stake in shares of Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after acquiring an additional 2,001,139 shares in the last quarter. Finally, Fisher Asset Management LLC increased its holdings in Johnson & Johnson by 11.5% during the 3rd quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock worth $3,927,981,000 after purchasing an additional 1,530,070 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on JNJ. Citigroup boosted their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Evercore set a $300.00 price objective on Johnson & Johnson in a report on Tuesday, October 20th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a report on Monday, August 3rd. Bank of America restated a “neutral” rating and set a $278.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Finally, Royal Bank Of Canada reduced their target price on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $275.92.

More Johnson & Johnson News

These are some of the JNJ news items that stood out recently:

• Positive Sentiment: JNJ has risen 10.4% since its latest earnings report, and State Street’s Health Care SPDR added shares on Nov. 10. These reports suggest continued investor interest, though neither guarantees further gains. Johnson & Johnson Up 10.4% Since Last Earnings Report State Street Health Care SPDR Adds Johnson & Johnson
• Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The notice provides no specific findings, but litigation-related uncertainty may weigh on sentiment. Pomerantz Law Firm Investigates Claims on Behalf of Johnson & Johnson Investors

Johnson & Johnson Stock Performance

JNJ stock traded up $2.26 during trading on Friday, hitting $285.78. 6,279,519 shares of the company’s stock traded hands, compared to its average volume of 7,472,752. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $193.55 and a 52 week high of $288.11. The stock has a fifty day moving average price of $266.97 and a two-hundred day moving average price of $249.85. The stock has a market capitalization of $687.95 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 2.80 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period last year, the firm posted $2.80 EPS. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio is 81.21%.

Insider Buying and Selling

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elizabeth Forminard sold 13,072 shares of the company’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,669 shares of company stock worth $16,898,386 over the last quarter. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.